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Abstract
Background: Membranoproliferative glomerulonephritis is a common pattern of glomerular injury in monoclonal
gammopathy, but has only rarely been associated with solid organ tumors, mainly lung, renal, gastric, breast,
and prostate. There have been two reported cases of membranoproliferative glomerulonephritis associated with
adenocarcinoma of the colon and rectum, although the association may be coincidental. We report a case where
nephrotic syndrome due to membranoproliferative glomerulonephritis developed in a patient with colorectal
carcinoma and elucidate some of the pathophysiological mechanisms underpinning this presentation.
Case presentation: A 54-year-old white man with a history of adenocarcinoma of the colon with metastasis to
the liver and ureter presented with a 1-week history of bilateral pedal edema, and worsening hypertension and
renal function. A renal biopsy confirmed membranoproliferative glomerulonephritis type I. Curative therapy for the
malignancy was not possible, so treatment was commenced with prednisolone with consequential biochemical
improvement in renal function and proteinuria, although his serum albumin remained low.
Conclusions: This case report illustrates an association between membranoproliferative glomerulonephritis and
metastatic colorectal carcinoma and adds to the evidence to consider malignancy to be an underlying pathology
among newly diagnosed cases of nephrotic syndrome. In the clinical setting, treatment of the underlying
malignancy should be first considered in patients with a tumor presenting with kidney disease which is
suspected to be paraneoplastic in etiology.
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Background
Nephrotic syndrome can be associated with various solid
organ tumors and lymphoproliferative diseases [1–3].
Membranous glomerulonephritis is the most common
underlying etiology [3, 4]. Membranoproliferative glom-
erulonephritis (MPGN) is a common pattern of glom-
erular injury in monoclonal gammopathy [4], but has
only rarely been associated with solid organ tumors,
mainly lung [5, 6], renal [5, 7], gastric [4], breast [4], and
prostate [5, 8]. There have been two reported cases of
MPGN associated with adenocarcinoma of the colon
and rectum [5, 9], although the association may be coin-
cidental. We report a case where MPGN developed in
the setting of chemotherapy for metastatic colorectal
cancer.
Case presentation
A 54-year-old white man was referred with a 1-week
history of bilateral pedal edema, worsening hyperten-
sion, and a rise in serum creatinine from 111 μmol/L
to 213 μmol/L over 2 weeks. He had microscopic
hematuria and proteinuria quantified at 24 grams/
day (see Additional file 1). His serum albumin was 24
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g/L compared with 35 g/L 2 weeks earlier. Other relevant
investigations included negative hepatitis B and C ser-
ology, weakly positive speckled antinuclear antibody
(ANA) titer of 160 (normal <40) with double-stranded
deoxyribonucleic acid (DNA) of 0 IU/mL (normal <7), nor-
mal ratio of serum free light chains, negative cryoglobulin
screen, negative serum protein electrophoresis, and a
normal C3 of 1.77 g/L and C4 of 0.38 g/L.
He had a background history of hypertension, ob-
structive sleep apnea, and a 3-year history of colorectal
carcinoma with hepatic metastasis. His initial treatment
included neoadjuvant chemotherapy with capecitabine
and bevacizumab, and 26 fractions of radiotherapy. He
then underwent a right hemicolectomy and a partial
right hemihepatectomy, followed by 6 months of cape-
citabine and bevacizumab. One year later, a new 74 mm
metastatic lesion developed in his residual right liver
lobe, and a 16 mm mucin-secreting adenocarcinoma oc-
curred at the left vesicoureteric junction, which was
managed by distal ureterectomy. He was recommenced
on capecitabine, bevacizumab, and cetuximab, and con-
tinued on this treatment until presentation with neph-
rotic syndrome.
A renal biopsy was diagnostic of MPGN type I. Func-
tioning glomeruli showed mesangial hypercellularity,
endocapillary proliferation, and double contours in capil-
lary loops. No hyaline deposits were noted in the capil-
lary loops and no segmental sclerosis was seen (Fig. 1a).
There was interstitial fibrosis and tubular atrophy to-
gether with lymphocytes, plasma cells, and eosinophils
in the scarred interstitium (Fig. 1b). Immunofluores-
cence showed moderate granular deposition of IgG
and C3 in the mesangial areas and around the capil-
lary loops. Electron microscopy showed deposits in
the mesangial, paramesangial, and subendothelial
regions. Focal duplication of the glomerular basement
membrane was seen and there was mild expansion of
mesangial matrix.
Curative therapy for the malignancy was not possible,
so treatment was commenced with prednisolone for the
renal disease. Four months later, his proteinuria had re-
duced to 1.4 grams/day, creatinine had improved to 155
μmol/L, and albumin returned to baseline of 31 g/L.
Discussion
This case highlights that MPGN can be associated with
malignancy, although the mechanism underpinning this
association has not been completely elucidated.
Little is known about the association between MPGN
and malignancy, although there is a wealth of published
information regarding nephrotic syndrome and malig-
nancy. As early as the 1960s, there were suggestions that
nephrotic syndrome may be related to thyroid cancers,
Hodgkin’s lymphoma, or chronic lymphocytic leukemia
[1]. Further, a more recent study analyzed approximately
8 million people in the Danish National Registry of Pa-
tients, estimating that that 4.7 % of patients who had
nephrotic syndrome (from a total of 4293 patients) had
underlying malignancy with lung cancer, multiple mye-
loma, and prostate cancer being most likely [10].
There are two main hypotheses which have been pro-
posed to explain the pathogenesis of the association be-
tween MPGN and malignancy. First, an undiagnosed
malignancy associated with immune complex deposition
may cause a glomerular disease-like paraneoplastic syn-
drome. While data are limited in MPGN, studies have
shown that paraneoplastic membranous nephropathy is
characterized by an increased number of inflammatory
cells in the glomeruli compared with that of idiopathic
membranous nephropathy [4, 11]. There is a greater
Fig. 1 a Periodic acid–Schiff stain, 100× magnification, showing features of membranoproliferative glomerulonephritis type 1. b Methenamine
silver stain, 200× magnification, highlighting double contour formation in capillary loops. Mesangial proliferation and segmental endocapillary
proliferation can also be seen
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prominence of the subtypes of IgG1 and IgG2 in the
renal biopsy samples of patients with paraneoplastic
membranous nephropathy compared with idiopathic
membranous nephropathy [12]. Second, viral infection
may have induced both glomerulopathy and cancer by
intrinsic viral oncogenic activity. It is possible that dis-
rupted renal clearance of biological mediators may be
associated with oncogenesis [13]. However, the most
likely explanation for the connection between virus latency
and tumorigenesis is that replicating viruses may initiate
cell death [14]. When latent viruses produce virions,
virus replication generates pathogen-associated molecular
patterns from partially synthesized viral chromosomes,
double-stranded ribonucleic acid (RNAs) and empty
capsids that trigger cellular DNA damage responses and
innate immune signaling. Toll-like receptor and interferon
signaling by virus infection is subsequently activated,
amplifying the innate response [14].
Remission of cancer has led to subsequent remission
of nephrotic syndrome. Reports have shown that pa-
tients who have paraneoplastic glomerulopathy second-
ary to renal cell carcinoma have undergone remission or
a reduction of proteinuria through either radical neph-
rectomy, nephron-sparing, partial nephrectomy, or
laparoscopic nephrectomy [15]. There are, however, no
reports that have specifically looked at the remission of
cancer in patients with MPGN. There is some evidence
for the use of prednisolone when cure of the cancer is
not an option. One case of MPGN developed after
surgical removal of a bronchial carcinoid tumor, but
responded to prednisolone therapy [16]. Furthermore,
there has been a case showing use of prednisolone for
paraneoplastic MPGN without ablation in a patient with
metastatic prostate cancer [7]. Moreover, paraneoplastic
glomerulopathy developed in a patient with minimal
change disease, who had retroperitoneal sarcoma, prob-
ably secondary to a T-cell-mediated response to malig-
nancy, which went into remission with corticosteroid
therapy [17]. Administration of corticosteroids was con-
sidered in this setting primarily because of the patient’s
high performance status.
The prognosis of MPGN in the setting of malig-
nancy is uncertain [18]. The presence of hyperten-
sion at presentation, severe nephrotic syndrome, and
renal insufficiency are known poor prognostic factors
among non-malignancy-associated nephrotic syn-
drome [18].
Conclusions
In summary, we report a case of an association between
MPGN and metastatic colorectal cancer. Clinicians need
to be vigilant about the possible paraneoplastic nature of
MPGN. Initial treatment of the underlying malignancy
should be the primary management in patients presenting
with kidney disease which is suspected to be paraneoplastic
in etiology, although prednisolone is an appropriate
therapy if cure of the cancer is not feasible.
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